Kornimate/medical-research-clean huggingface dataset:
outcomes after pci of the aneurysmatic right coronary artery

Conditions: Coronary Disease; Coronary Artery Ectasia; Right Coronary Artery Occlusion; Right Coronary Artery Stenosis; STEMI

Summary: this study aims to evaluate procedural and clinical outcomes of acute coronay syndrome (acs) patients with aneurysmatic culprit right coronary artery (rca).

the investigators sought differences in procedural (slow-flow, no-reflow, distal embolisation,thrombolysis in myocardial infarction final flow (timi) etc.) and in immediate and long-term clinical outcomes between several subgroups such as index vs staged percutaneous coronary intervention (pci), premedication vs none, use of iib/iiia inhibitors vs none, bare metal stent (bms) vs drug eluting stent (des), ultrathin des vs thick des, durable polymer vs bioresorbable or free polymer etc. the investigators also want to investigate the efficacy of different technical manoeuvres involved in resolving high thrombotic burden before stent deployment, such as thrombus aspiration, dilatation, intracoronary infusion of adenosine or thrombolytic agents, direct stenting etc.). long-term follow-up includes target vessel failure (cardiac death, target vessel mi, clinically-driven target vessel revascularisation), define or probable stent thrombosis, target vessel revascularisation for acs, clinically driven target vessel revascularisation and intrastent restenosis.

Eligibility criteria:
inclusion criteria: * patients with acs of the aneurysmatic or ectasic rca * patient with at least 6 months clinical or angiographic follow-up * patients with accurate procedural and clinical records (particularly use of drugs before, during and after procedure, according to rca pci procedure (index or staged). exclusion criteria: * elective aneurysmatic or ectasic rca pci * patient with lack of accurate procedural and clinical data * patient with lack of clinical or angiographic follow up

Keywords: pci acute coronary syndrome aneurysmatic right coronary artery
study of biomarkers in patients of sepsis complicated with gastrointestinal dysfunction

Conditions: Sepsis; Gastrointestinal Dysfunction

Summary: 1. title: study of biomarkers in patients of sepsis complicated with gastrointestinal dysfunction 2. research center: single-center study. 3. design of the research: a prospective and cohort study. 4. object of the research: patients with age≥18 years those who meet the diagnostic criteria of sepsis 3.0 complicated with gi and grouped into gi group and non-gi adults as control. 5. sample size of the research: not less than 30 patients in each group. 6. research approach: after admission to icu, patients were assigned to the indicated groups according to the criteria. in addition, blood samples were collected within 24 hours for detecting serum levels of ho-1, pink1, plk1as well as oxidative stress and inflammatory markers.for those who requiring intestinal surgery as treatment, the intestinal tissue specimens are retained. 7. aim of the research: the find out the potential biomarkers in serum to help the diagnose and management of gastrointestinal dysfunction in septic patients. 8. statistical analysis: analytical study. 9. the estimated duration of the study#1-2 years.

this study is a single-center, prospective, cohort study. in this study, the serum samples of septic patients complicated with or without gi are detected. the serum levels of ho-1, pink1, plk1as well as oxidative stress and inflammatory markers are compared in different groups. for those who requiring intestinal surgery as treatment, the intestinal tissue specimens are retained. meanwhile, the clinical symptoms, intestinal motility indicators and intestinal barrier indicators are recorded. in addition, a biomarker model was established to provide important reference for diagnose and management of gastrointestinal dysfunction in septic patients.

Eligibility criteria:
inclusion criteria: 1. at least 18 years old 2. patients with sepsis who meet the criteria for sepsis 3.0 3. patients complicated gastrointestinal dysfunction with agi grade ii or above 4. agree to participate in this study and sign informed consent exclusion criteria: 1. refuse to participate in this study 2. those who have chronic gastrointestinal diseases such as crohn's disease and ulcerative colitis 3. those who have recently used gastrointestinal motility drugs and within 5 times the half-life 4. those who are participating in other drug clinical trials 5. patient with hiv infection, patients in pregnancy or breast stage 6. in the opinion of the attending physician or researcher, there are other conditions that are not appropriate for the study

Keywords: sepsis gastrointestinal dysfunction biomarkers
long term outcomes after surgery for anal fistula

Conditions: Fistula in Ano

Summary: anal fistula is a common condition with a wide variety of clinical presentations, which can make evaluation and treatment challenging and surgical outcomes uncertain. this study was undertaken to identify lessons learned in the surgical treatment of 483 patients over a 20- year period leading to a pragmatic approach to treatment of this condition.

the wide array of variations of anal fistulas makes them challenging both to classify and to treat. the aim of the study is to determine if a systematic approach to their evaluation and surgical treatment, regardless of how one wishes to classify them, can be based on careful assessment of sphincter length and of the anatomical and etiological characteristics of the fistula.

Eligibility criteria:
inclusion criteria: * anal fistulas exclusion criteria: * none

Keywords: anal fistula fistulotomy ano-rectal advancement flap sphincter saving
chest pain pilot study

Conditions: Chest Pain; Gastroesophageal Reflux

Summary: the purpose of this study is to compare the efficacy of nexium® with placebo in relief of acid related pain or discomfort in the chest.


Eligibility criteria:
inclusion criteria: * pain or discomfort in the chest without any identifiable cause and severe enough for the patient to seek primary medical or similar care. * history of pain or discomfort in the chest for at least the last two weeks prior to enrollment. exclusion criteria: * signs, symptoms or relevant investigations suggestion present symptomatic coronary heart disease. * patients whose pain or discomfort in the chest warrants urgent cardiac investigation.

Keywords: gastroesophageal reflux disease gerd
the specific elastance in ards patients: a pediatric study

Conditions: Pediatric ARDS

Summary: aim of this study is to assess lung specific elastance in a population of pediatric patients with acute respiratory distress syndrome (ards) treated with mechanical ventilation, and in a pediatric population of icu patients with healthy lung which are treated with mechanical ventilation for other clinical purposes.


Eligibility criteria:
inclusion criteria: * ards (berlin definition criteria) or mechanical ventilation in healthy lungs exclusion criteria: * hemodynamic instability * lung diseases other than ards * parental refuse

Keywords: ards lung specific elastance pediatric patients
study among people living with hiv and their health professionals of associated factors of resilience to self-stigma

Conditions: HIV Infections

Summary: this study is perform to study the effect of psychological and psychosocial factors associated with resilience to the self-stigmatization of people living with hiv

epidemiological and sociological survey carried out with patients and their caregivers in the chus and chgs of france via the corevih from 01/17/2022 to 02/17/2022. primary endpoint: self-stigmatization as experienced by plwha will be explored through a patient questionnaire secondary endpoints:the main explanatory variables will be studied by means of a custom questionnaire intended for the patient and covering psychological flexibility, social provisions, avoidance and fusion mechanisms, quality of life, anxiety and depression. the socio-demographic explanatory variables will be collected by questionnaire, covering the following areas: sex, age, geographical origin, insecurity, drug use, sexuality, family context, employment, leisure, care environment. a questionnaire intended for caregivers will study the self-stigmatization perception of the people they care for and the means implemented to fight against self-stigmatization. anonymous data will be reported in redcap. the population will be described by numbers and percentages for categorical variables and by the mean ± standard deviation or the median \[interquartile range\] for the quantitative variables, with regard to their statistical distribution. normality will be studied by the shapiro-wilk test and / or by histogram. as far as possible, graphical representations will be associated with the analyzes.

Eligibility criteria:
inclusion criteria: * for patients: adult patient, male or female, infected with hiv medically monitored in a hospital department involved in the investigation. * affiliation to a social security scheme for caregivers:caregiver caring for people living with hiv as part of a hospital service involved in the survey (doctor, ide, psychologist, other ...). exclusion criteria: * minor patient * refusal of participation * persons under guardianship, guardianship or legal protection

Keywords: hiv stigmatization self-stigma
a comparative study of patient satisfaction between continued administration of previous antipsychotics versus switched administration to paliperidone er in non-satisfied patients with previous antipsychotic drug

Conditions: Schizophrenia

Summary: the purpose of this study is to compare the patient satisfaction between continued administration of previous antipsychotics versus switched administration to paliperidone er in non-satisfied patients with previous (paliperidone)

this is a randomized (patients are assigned to intervention by chance), prospective, open-label (all people involved know the identity of the assigned drug), switch study designed to evaluate patient-assessed medication satisfaction after 12 weeks of treatment in patients with schizophrenia. the total duration of this study is 12 weeks. outpatients who treated atypical antipsychotics and report dissatisfaction (medication satisfaction questionnaire \[msq\] \<4) with their current treatment response are eligible to participate in the study. patients will be randomized into two groups, 1) patients randomized to an immediate initiation of paliperidone er for a total 12 weeks 2) patients randomized to a delayed initiation will continue their previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone er at day 56 for 4 weeks. during the study treatment optimization will be done by dose adjustment (dose increase or decrease) and by adding psychotropic agents except the antipsychotics.

Eligibility criteria:
inclusion criteria: * must be diagnosed with schizophrenia according to the diagnostic and statistical manual of mental disorders (dsm-iv) criteria * have taken atypical antipsychotics (aripiprazole, olanzapine, risperidone) at least 6 weeks prior to start of study. * have medication satisfaction questionnaire (msq) score of ≤3 * competent patients who manage to answer the questionnaires exclusion criteria: * have had a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome * have had relevant history of or current presence of any significant or unstable cardiovascular, respiratory, neurological (including seizures or significant cerebrovascular), renal, hepatic, hematologic, endocrine, immunologic, morbid obesity (bmi≥40), or other systemic disease * had received two or more different kind of antipsychotics. * had a history of taking paliperidone extended release (er). * allergy or hypersensitivity to risperidone or paliperidone er. * have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months. * have had medication satisfaction questionnaire (msq) score\>3 * have been hospitalized for longer than 8 continuous weeks during the past 6 months * had history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic) or inability to swallow the oral tolerability medication whole with the aid of water for patients requiring oral tolerability testing * current substance dependence (dsm-iv) or past history of dependence (more than 6 months)

Keywords: schizophrenia paliperidone er antipsychotics mental disorder comparative study
the effect of pregnancy on the pk of isentress®: a longitudinal investigation in the second and third trimesters

Conditions: HIV; Pregnancy

Summary: the purpose of this study is to determine whether pregnancy affects the blood concentrations of raltegravir by comparing the second trimester and third trimester drug concentrations with post partum.


Eligibility criteria:
inclusion criteria: * hiv infected * pregnant * at least 18 years of age * planning to initiate or currently received raltegravir as part of an antiretroviral regimen with plans to continue at least 8-10 weeks post partum exclusion criteria: * less than 18 years of age * hemoglobin \<9 g/dl or hematocrit \<27.3 at screening
yoga-based exercise program for temporomandibular disorders

Conditions: Temporomandibular Disorders; Myofascial Pain Dysfunction Syndrome; Temporomandibular Joint Pain; Range of Motion; Yoga; Quality of Life

Summary: aims:the study was conducted to investigate the effect of yoga-based exercise program on pain, range of motion(rom), sleep quality, depression and quality of life in female patients with myofascial pain dysfunction(mpd) of temporomandibular disorders . methods: mpd will be included in the study. yoga based exercise program will be performed to the first group as 3 times in a week for 6 weeks. the second group will be the control group. outcome measurements; pain ,sleep quality, depression and quality of life will be evaluated. evaluations will be repeated before and 6 weeks after exercise.

total 46 female patients between the ages of 20-50 planned to include in the study. in the study, 42 volunteers divided into two groups as yoga group (group 1) and control group (group 2). as a result of randomization, those chose 1 were taken in group 1, 2 were included in group 2. yoga-based exercises performs for 6 weeks and 3 days in a week for the first group. the second group will be taken in the waiting list to be included in the program as a control group. yoga-based exercises perform by a physiotherapist has yoga training, by consisting of 10-person groups, 6 weeks, 3 days in a week for a total of 18 sessions. yoga-based exercises are hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises and lasts about one hour. before the treatment, evaluations made immediately after the 6-weeks exercise program ended. as the primary outcome measures; jaw pain visual analog scale (vas), neck pain and disability scale (npds), neck and jaw range of motion (rom) measurements; for secondary outcome measurements; the pittsburg sleep quality index (puqi), beck depression inventory (bdi) and short form 36 (sf36) are used. all measurements are repeated at the 6th week after yoga application and datas compared with the baseline measurements.

Eligibility criteria:
inclusion criteria: * female patients aged 20-50 years diagnosed with mpd(myofascial pain dysfunction) syndrome according to the research diagnostic criteria for temporomandibular disorders exclusion criteria: * those with orthopedic problems such as degenerative arthritis and traumatic injuries, took physiotherapy program in the last 3 months and drug users were not included in the study.
remote patient monitoring for patients with heart failure in france

Conditions: Heart Failure; Patient Empowerment; Cardiac Failure

Summary: the goal of this multicenter observational longitudinal cohort study is to evaluate the ability of a remote patient monitoring (rpm) program to prevent cardiac decompensation by detecting weak signals of decompensation early in patients with chronic heart failure in france. the main question it aims to answer is whether an rpm solution can provide the improvement in overall patient survival participants will answer to questionnaires provided by the rpm solution for the follow-up of their condition. researchers will compare the following cohorts to see if rpm can improve their condition: * cohort 1: using rpm for follow-ups. * cohort 2: conventional care and not using any devices and solutions for the follow-ups.

telesat study is a national-scale observational prospective cohort study conducted in france from august 2018 to december 2022. the study was conducted using the french national health data system known as the système national des données de santé (snds) which covers approximately 99% of the french population.

Eligibility criteria:
inclusion criteria: * residing in france * having heart failure * adults over the age of 18 years * new york heart association (nyha) score≥2 and brain natriuretic peptid (bnp)\>100 pg/ml or n-terminal pro bnp\>1000 pg/ml or prior hospitalization for heart failure exclusion criteria: * physician's assessment deemed patient not be physically or mentally able to be remotely monitored * had chronic dialysis * severe liver failure * the presence of any other medical condition resulting in a less than one-year life expectancy, * an estimated low adherence to treatment * lack of a stable place of residence * refusing to participate in the program ineligible.

Keywords: remote patient monitoring heart failure cardiac decompensation telehealth
positron emission tomography imaging with [f-18] flt compared to [f-18] fdg in cancer patients for treatment evaluation

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to investigate the clinical value of serial quantitative \[f-18\] flt as a pet imaging tool in head and neck cancer patients clinically scheduled with radiation or radiation-chemotherapy combination in terms of safety and efficacy. standard \[f-18\] fdg pet will be the active comparator.


Eligibility criteria:
inclusion criteria: 1. patient provides written informed consent and is willing to comply with protocol requirements 2. patient is at least 18 years of age on the day of dosing (male or female of any race or ethnicity) 3. patient is capable of lying still in the pet scanner for the protocol required time frame(s) 4. patient has a diagnosis of one of the following malignancies (tnm staging system): * lung cancer (t3 grade up, node positive, but no metastatic disease) * head and neck cancer (t3 grade up, node positive, but no metastatic disease) 5. patient has undergone a comparative, diagnostic procedure with lesion(s) visible, other than ultrasound, that includes, but is not limited to computed tomography (ct), magnetic resonance imaging (mri), nuclear medicine imaging, endoscopy, laparoscopy, standard abdominal x-ray, biopsy and/or surgery for one of the above mentioned areas 6. patient is scheduled to start radiotherapy or a chemoradiotherapy regimen for curative intent 7. as a part of his/her standard radiotherapy or chemoradiotherapy regimen, patient is scheduled to have clinical \[f-18\] fdg pet scans pre treatment and post treatment (at about 4 weeks (±1 week) after the start of therapy) 8. patient is scheduled to have the investigational, pre treatment \[f-18\] flt pet scan recommended to be within ± 2 days of the clinical, pre treatment \[f-18\] fdg pet scan 9. patient has not received or intends to receive 5-fluorouracil (5-fu-chemotherapeutic agent) 10. patient has a score of greater than or equal to (≥) 60% on the karnofsky performance status scale exclusion criteria: exclude a patient from this study if the patient does not fulfill the inclusion criteria, or if any of the following conditions are observed: 1. patient is a pregnant or lactating female. these methods will be used to exclude the possibility of pregnancy: * by testing on site at the institution (serum or urine βhcg) within 48 hours prior to the start of each investigational product administration, * by surgical history (eg, tubal ligation or hysterectomy), * by patient's history of being post menopausal with a minimum 1 year without menses. 2. patient is undergoing treatment with palliative intent 3. patient has received an investigational compound and/or medical device within 14 days before admission into this study 4. patient has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations 5. patient is determined by the investigator that he/she is clinically unsuitable for the study.
a study to assess the safety, tolerability and efficacy of nva237 versus placebo

Conditions: Chronic Obstructive Pulmonary Disease

Summary: a study to assess the safety, tolerability and efficacy of nva237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: 1. diagnosis of copd (moderate-to-severe as classified by the global initiative for chronic obstructive lung disease (gold) guidelines, 2008) and: * smoking history of at least 10 pack-years * post-bronchodilator fev1 \< 80% and ≥ 30% of the predicted normal value * post-bronchodilator fev1/fvc (forced vital capacity) \< 70% exclusion criteria: 1. patients who have had a lower respiratory tract infection within 6 weeks prior to visit 1 2. patients with concomitant pulmonary disease 3. patients with a history of asthma 4. any patient with lung cancer or a history of lung cancer 5. patients with a history of certain cardiovascular comorbid conditions 6. patients with a known history and diagnosis of alpha-1 antitrypsin deficiency 7. patients in the active phase of a supervised pulmonary rehabilitation program 8. patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents other protocol-defined inclusion/exclusion criteria may apply

Keywords: copd nva fev1